IL3 and CD4+/CD56+ hematodermic neoplasm: Tagraxofusp is an IL3/diphtheria toxin fusion protein that is FDA-approved for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare malignancy that has high levels of CD123 expression [101].